Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature

被引:0
作者
O. Shovman
Y. Shoenfeld
P. Langevitz
机构
[1] Chaim Sheba Medical Center,Zabludowicz Center for Autoimmune Diseases
[2] Tel-Aviv University,Incumbent of the Laura Schwarz
[3] Tel-Aviv University,Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine
来源
Immunologic Research | 2015年 / 61卷
关键词
Tocilizumab; Rheumatoid arthritis; Neutropenia;
D O I
暂无
中图分类号
学科分类号
摘要
One of the adverse events of tocilizumab (TCZ) is a transient, dose-dependent neutropenia. The recommendations of the Summary of Product Characteristics state that this neutropenia should be managed according to the absolute neutrophil count (ANC). However, the approach to a patient who had a history of neutropenia induced by previous DMARDs and developed TCZ-induced neutropenia remains unclear. We would like to report a series of four patients with rheumatoid arthritis who developed Grade 2 neutropenia (ANC 1–1.5 × 109/L) following intravenous TCZ treatment at a dose of 8 mg/kg. All of them had a previous history of neutropenia (Grade 2 or Grade 3) due to Etanercept (three patients) and Sulfasalazine (one patient). Therefore, we decided to decrease the TCZ dosage by 10–20 % approximately. Reducing of the dosage did not have any influence on the efficacy of TCZ, and all of our patients remained in clinical remission. The mechanisms underlying neutropenia induced by Tocilizumab, Etanercept and Sulfasalazine are also discussed in this article.
引用
收藏
页码:164 / 168
页数:4
相关论文
共 42 条
  • [1] Genovese MC(2008)Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study Arthritis Rheum 58 2968-2980
  • [2] McKay JD(2010)Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions Mod Rheumatol 20 222-232
  • [3] Nasonov EL(2009)Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis J Rheumatol 36 459-460
  • [4] Nishimoto N(2014)A14: neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis Arthritis Rheumatol 66 S23-S24
  • [5] Ito K(2014)A45: neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with polyarticular-course juvenile idiopathic arthritis Arthritis Rheumatol 66 S67-S68
  • [6] Takagi N(2007)Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges Clin Rheumatol 26 1527-1529
  • [7] Nakamura I(2008)Three significant cases of neutropenia with etanercept Rheumatology (Oxford) 47 376-377
  • [8] Omata Y(2009)Adalimumab-induced neutropenia in a patient with rheumatoid arthritis Joint Bone Spine 76 312-313
  • [9] Naito M(2006)Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis Ann Rheum Dis 65 1678-1679
  • [10] De Benedetti F(2012)Re-challenge with Etanercept in patients with Etanercept-induced Neutropenia Clin Rheumatol 31 151-155